Patents Represented by Attorney, Agent or Law Firm Jane E. R. Potter
-
Patent number: 7361484Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: February 8, 2007Date of Patent: April 22, 2008Assignee: Chiron CorporationInventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Patent number: 7329741Abstract: The present invention is a novel nucleic acid sequence which hybridizes to SEQ ID NO:6 or fragments thereof under stringent conditions, or fragments thereof. The invention also includes diagnostic assays, expression vectors, control sequences, antisense molecules, ribozymes, and host cells to express the polypeptide encoded by the nucleic acid sequence. The present invention also includes claims to the polypeptide sequence coded by the nucleic acid sequences.Type: GrantFiled: December 4, 2002Date of Patent: February 12, 2008Assignee: Chiron CorporationInventor: David Duhl
-
Patent number: 7291725Abstract: Inhibitors of human Sos1, including antisense oligonucleotides, methods, and compositions specific for human Sos1, are provided. Methods of using the compositions for modulating Sos1 expression and for regulating cell growth, particularly tumor cell growth, are also provided.Type: GrantFiled: June 25, 2003Date of Patent: November 6, 2007Assignee: Chiron CorporationInventors: Birgit K. Jaitner, Wendy J. Fantl
-
Patent number: 7279554Abstract: The invention provides polynucleotides encoding Notch receptor ligands, encoded polypeptides, and antibodies specific to the polypeptides. Also provided are methods and compositions for enhancing or inhibiting angiogenesis as well as modulating immune responses.Type: GrantFiled: August 20, 2003Date of Patent: October 9, 2007Assignee: Chiron CorporationInventors: Vivien Chan, Michael Rohan, Lewis T. Williams
-
Patent number: 7259248Abstract: This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.Type: GrantFiled: January 29, 2002Date of Patent: August 21, 2007Assignees: Chiron Corporation, Kyoto UniversityInventors: Nobuyuki Itoh, W Michael Kavanaugh
-
Patent number: 7135321Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: October 20, 2003Date of Patent: November 14, 2006Assignee: Chiron CorporationInventors: Stephen D Harrison, John A Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y Fang, Doris G Coit, Steve H Nguyen, Angelica Medina-Selby
-
Patent number: 7081517Abstract: A polynucleotide sequence as shown in SEQ ID NO:1 is associated with metastatic potential of cancer cells, especially breast cancer cells. Methods are provided for determining the risk of metastasis of a tumor, by determining whether a tissue sample from a tumor expresses a polypeptide or mRNA encoded by a polynucleotide as shown in SEQ ID NO:1. Also provided are therapeutic methods and compositions.Type: GrantFiled: July 18, 2002Date of Patent: July 25, 2006Assignee: Chiron CorporationInventors: Joerg Kaufmann, Greg Harrowe, Christoph Reinhard, Sanmao Kang
-
Patent number: 6974867Abstract: Inhibitors of KIAA0175 are provided that reduce the expression or biological activities of KIAA0175, p53 and/or p21 in a mammalian cell. KIAA0175 inhibitors include anti-sense molecules, ribozymes, antibodies and antibody fragments, proteins and polypeptides as well as small molecules. KIAA0175 inhibitors find use in compositions and methods for decreasing KIAA0175, p53 and/or p21 gene expression as well as methods for increasing the chemo and/or radiosensitivity of mammalian cells, including tumor cells, methods for decreasing the side effects of cancer therapy and methods for treating neoplastic diseases.Type: GrantFiled: May 30, 2001Date of Patent: December 13, 2005Assignee: Chiron CorporationInventors: Bin Wu, Todd W. Seeley, Lewis T. Williams
-
Patent number: 6825333Abstract: This invention relates to mouse and human EGFH2, and to variants thereof and to polynucleotides encoding EGFH2. This invention also relates to therapeutic agents related to the polynucleotides and proteins.Type: GrantFiled: August 15, 2000Date of Patent: November 30, 2004Assignee: Chiron CorporationInventors: W. Michael Kavanaugh, Hui Cen, Pauline Lee
-
Patent number: 6809194Abstract: Inhibitors of human Akt3, including antisense oligonucleotides, methods, and compositions specific for human Akt3, are provided. Methods of using the compositions for modulating Akt3 expression and for regulating cell growth, particularly tumor cell growth, are also provided.Type: GrantFiled: May 8, 2001Date of Patent: October 26, 2004Assignee: Chiron CorporationInventors: Christoph Reinhard, Anne B. Jefferson
-
Patent number: 6797695Abstract: This invention relates to human fibroblast growth factor (hFGF-20), and to variants thereof and to polynucleotides encoding FGF-20. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, to methods of treating neuronal degenerative disease such as Parkinson's disease and to methods of treating disorders of the cochlea including those causing hearing loss. The invention also relates to rat fibroblast growth factor (rFGF-20), and to variants thereof and polynucleotides encoding rFGF-20.Type: GrantFiled: October 20, 2000Date of Patent: September 28, 2004Assignees: Kyoto University, Chiron CorporationInventors: Nobuyuki Itoh, Michael Kavanaugh
-
Patent number: 6794145Abstract: Isolated nucleic acid molecules are provided which encode Fkhsf, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Utilizing assays based upon the nucleic acid sequences disclosed herein (as well as mutant forms thereof), numerous molecules may be identified which modulate the immune system.Type: GrantFiled: October 24, 2000Date of Patent: September 21, 2004Assignee: Darwin Discovery Ltd.Inventors: Mary E. Brunkow, Eric W. Jeffery, Kathryn A. Hjerrild, Fred Ramsdell
-
Patent number: 6716624Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.Type: GrantFiled: July 31, 2002Date of Patent: April 6, 2004Assignee: Chiron CorporationInventors: Stephen D. Harrison, John A. Hall, Maria Calderon-Cacia, Ziyang Zhong, Eric Y. Fang, Doris G. Coit, Steve H. Nguyen, Angelica Medina-Selby
-
Patent number: 6716626Abstract: This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.Type: GrantFiled: November 16, 2000Date of Patent: April 6, 2004Assignees: Chiron Corporation, Kyoto UniversityInventors: Nobuyuki Itoh, Michael Kavanaugh
-
Patent number: 6703221Abstract: The invention provides polynucleotides encoding Notch receptor ligands, encoded polypeptides, and antibodies specific to the polypeptides. Also provided are methods and compositions for enhancing or inhibiting angiogenesis as well as modulating immune responses.Type: GrantFiled: August 17, 2000Date of Patent: March 9, 2004Assignee: Chiron CorporationInventors: Vivien Chan, Michael Rohan, Lewis T. Williams
-
Patent number: 6677117Abstract: A human tumor suppressor gene termed polyhomeotic 2 and its expression products can be used as therapeutic, prognostic, and diagnostic tools for proliferative and developmental disorders. Nucleotide sequences of the gene can also be used to identify a p34.3 region of a human chromosome 1.Type: GrantFiled: September 1, 2000Date of Patent: January 13, 2004Assignee: Chiron CorporationInventor: Filippo M. Randazzo
-
Patent number: 6673911Abstract: A human oncogene and its expression products can be used as diagnostic, prognostic, and therapeutic tools for neoplastic disorders. Nucleotide sequences of the gene can also be used to identify a p34.3 region of a human chromosome 1.Type: GrantFiled: April 11, 2000Date of Patent: January 6, 2004Assignee: Chiron CorporationInventor: Filippo M. Randazzo
-
Patent number: 6664054Abstract: The present invention provides the art with the DNA coding sequences of polynucleotides that are up- or down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.Type: GrantFiled: January 31, 2001Date of Patent: December 16, 2003Assignee: Chiron CorporationInventor: Guilia C. Kennedy
-
Patent number: 6635748Abstract: Gene sequences as shown in SEQ ID NO:1-18 have been discovered and isolated, and found to be significantly associated with metastatic spread of breast and colon cancer cells to other organs. Methods are provided for determining the risk of metastasis of a breast or colon tumor, which involve determining whether a tissue sample from a tumor expresses a polypeptide encoded by a gene as shown in SEQ ID NOS:1-18, or a substantial portion thereof. One of the gene sequences encodes a novel aspartyl protease termed CSP56, which can be used to provide reagents and methods for determining which tumors are likely to metastasize and for suppressing metastases of these tumors. Clinicians can use this information to predict which tumors will metastasize to other organs and to provide relevant therapies to appropriate patients.Type: GrantFiled: December 17, 1998Date of Patent: October 21, 2003Assignee: Chiron CorporationInventors: Hong Xin, Klaus Giese
-
Patent number: 6589745Abstract: A human gene termed CIF130 and its expression products can alter the spatial or temporal patterns of mitosis or cell cycle progression of a human cell. Methods of treating disorders involving alterations in the regulation of mitosis or cell cycle progression utilize the gene and its expression product. Genes whose expression is dependent upon CIF130 expression can be identified.Type: GrantFiled: May 15, 2002Date of Patent: July 8, 2003Assignee: Chiron CorporationInventor: Joerg Kaufmann